Heartland Advisors Inc. decreased its position in shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) by 4.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 124,260 shares of the medical instruments supplier’s stock after selling 5,480 shares during the period. Becton, Dickinson and Company comprises 1.1% of Heartland Advisors Inc.’s investment portfolio, making the stock its 15th biggest position. Heartland Advisors Inc.’s holdings in Becton, Dickinson and Company were worth $22,243,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Moneco Advisors LLC lifted its stake in Becton, Dickinson and Company by 2.6% in the third quarter. Moneco Advisors LLC now owns 2,071 shares of the medical instruments supplier’s stock worth $371,000 after acquiring an additional 52 shares during the last quarter. Brown Lisle Cummings Inc. increased its position in shares of Becton, Dickinson and Company by 9.2% in the 2nd quarter. Brown Lisle Cummings Inc. now owns 644 shares of the medical instruments supplier’s stock valued at $97,000 after purchasing an additional 54 shares during the last quarter. Pension & Wealth Management Advisors Inc. increased its position in shares of Becton, Dickinson and Company by 12.3% in the 3rd quarter. Pension & Wealth Management Advisors Inc. now owns 510 shares of the medical instruments supplier’s stock valued at $94,000 after purchasing an additional 56 shares during the last quarter. Brighton Jones LLC raised its holdings in shares of Becton, Dickinson and Company by 0.7% in the 3rd quarter. Brighton Jones LLC now owns 8,942 shares of the medical instruments supplier’s stock valued at $1,601,000 after purchasing an additional 58 shares in the last quarter. Finally, Elevation Point Wealth Partners LLC raised its holdings in shares of Becton, Dickinson and Company by 3.7% in the 2nd quarter. Elevation Point Wealth Partners LLC now owns 1,692 shares of the medical instruments supplier’s stock valued at $256,000 after purchasing an additional 60 shares in the last quarter. 86.97% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
BDX has been the subject of a number of analyst reports. TD Cowen boosted their target price on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the stock a “hold” rating in a research note on Wednesday, August 5th. Bank of America raised their price target on Becton, Dickinson and Company from $185.00 to $200.00 and gave the company a “neutral” rating in a research note on Monday, August 31st. Citigroup lifted their price target on Becton, Dickinson and Company from $208.00 to $241.00 and gave the stock a “buy” rating in a report on Friday, November 6th. Weiss Ratings raised Becton, Dickinson and Company from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, November 4th. Finally, Zacks Research upgraded Becton, Dickinson and Company from a “hold” rating to a “strong-buy” rating in a report on Wednesday, October 21st. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Becton, Dickinson and Company has an average rating of “Moderate Buy” and an average target price of $197.47.
Read Our Latest Research Report on Becton, Dickinson and Company
Becton, Dickinson and Company Stock Down 0.6%
BDX stock opened at $214.83 on Thursday. The stock has a market cap of $59.19 billion, a P/E ratio of 51.85, a PEG ratio of 3.61 and a beta of 0.22. The company has a current ratio of 0.87, a quick ratio of 0.54 and a debt-to-equity ratio of 0.54. Becton, Dickinson and Company has a twelve month low of $140.11 and a twelve month high of $220.36. The company’s 50 day moving average is $192.98 and its two-hundred day moving average is $170.76.
Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last issued its earnings results on Thursday, November 5th. The medical instruments supplier reported $4.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.07 by $0.08. Becton, Dickinson and Company had a net margin of 5.66% and a return on equity of 14.90%. The business had revenue of $5.27 billion during the quarter, compared to analysts’ expectations of $5.11 billion. During the same quarter in the prior year, the business posted $3.96 EPS. The company’s revenue for the quarter was up 5.4% on a year-over-year basis. Research analysts expect that Becton, Dickinson and Company will post 13.21 earnings per share for the current fiscal year.
Becton, Dickinson and Company Increases Dividend
The business also recently declared a quarterly dividend, which will be paid on Thursday, December 31st. Investors of record on Thursday, December 10th will be given a $1.06 dividend. This represents a $4.24 dividend on an annualized basis and a yield of 2.0%. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $1.05. The ex-dividend date of this dividend is Thursday, December 10th. Becton, Dickinson and Company’s dividend payout ratio is presently 102.42%.
Becton, Dickinson and Company declared that its board has initiated a share repurchase program on Thursday, November 5th that permits the company to buy back 10,000,000 outstanding shares. This buyback authorization permits the medical instruments supplier to purchase up to 3.6% of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s leadership believes its shares are undervalued.
Insiders Place Their Bets
In other Becton, Dickinson and Company news, CEO Thomas Polen, Jr. sold 2,993 shares of the company’s stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $210.00, for a total value of $628,530.00. Following the completion of the transaction, the chief executive officer owned 110,163 shares in the company, valued at $23,134,230. This represents a 2.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Feld sold 165 shares of the company’s stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $188.49, for a total transaction of $31,100.85. Following the completion of the transaction, the executive vice president owned 19,720 shares of the company’s stock, valued at $3,717,022.80. This represents a 0.83% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 3,310 shares of company stock valued at $688,650. 0.40% of the stock is owned by corporate insiders.
Becton, Dickinson and Company Profile
Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops and manufactures products used in healthcare, clinical laboratories and life sciences research. Founded in 1897, the company has a long history of producing medical devices and supplies. BD’s products include syringes, needles, infusion systems and medication-management technologies, as well as equipment and supplies for collecting and processing clinical specimens. The company also provides diagnostic systems, laboratory instruments and tools used in areas such as cell analysis and biomedical research.
See Also
- Five stocks we like better than Becton, Dickinson and Company
- Lowe’s Earnings Beat Looked Strong Until a 34-Cent Tariff Refund Changed the Math
- Grounded at 52-Week Lows: When Will Boeing Stock Take Flight?
- Apple’s Next Margin Defense Could Be Hiding in Your Wallet
- From Berlin to Brussels: Tesla’s $3.3 Billion Robotaxi Gamble
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX – Free Report).
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.
